Clinical Trial Update: 28-day Repeat Dose Study of GSK573719 [Phase 2]

View source ↗

Summary

A Phase 2 28-day repeat-dose study of GSK573719 in chronic obstructive pulmonary disease has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK573719

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2014-02-24